<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">sechenov</journal-id><journal-title-group><journal-title xml:lang="en">Sechenov Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Сеченовский вестник</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2218-7332</issn><issn pub-type="epub">2658-3348</issn><publisher><publisher-name>Сеченовский Университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47093/2218-7332.2025.16.4.1344</article-id><article-id custom-type="elpub" pub-id-type="custom">sechenov-1344</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INTERNAL MEDICINE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВНУТРЕННИЕ БОЛЕЗНИ</subject></subj-group></article-categories><title-group><article-title>Familial co-occurrence of diffuse leiomyomatosis and Alport syndrome: a clinical case report</article-title><trans-title-group xml:lang="ru"><trans-title>Семейное сочетание диффузного лейомиоматоза и синдрома Альпорта: клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-8421-9592</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Болтабоева</surname><given-names>М.</given-names></name><name name-style="western" xml:lang="en"><surname>Boltaboeva</surname><given-names>М.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Болтабоева Мукаддас, PhD, ассистент кафедры госпитальной педиатрии</p><p>ул. С.Ю. Отабекова, д. 1, г. Андижан, 170100</p></bio><bio xml:lang="en"><p>Мuqaddas Boltaboeva, PhD, Assistant Professor, Department of Hospital Pediatrics</p><p>1, S.Yu. Otabekova str., Andijan, 170100</p></bio><email xlink:type="simple">Doctormeeeee1999@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7195-2542</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хайдаров</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Haydarov</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хайдаров Абдулхамид, студент</p><p>ул. С.Ю. Отабекова, д. 1, г. Андижан, 170100</p></bio><bio xml:lang="en"><p>Abdulhamid Haydarov, Student</p><p>1, S.Yu. Otabekova str., Andijan, 170100</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-2637-1932</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ганиева</surname><given-names>М.</given-names></name><name name-style="western" xml:lang="en"><surname>Ganieva</surname><given-names>M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ганиева Марифат, канд. мед. наук, доцент кафедры госпитальной педиатрии</p><p>ул. С.Ю. Отабекова, д. 1, г. Андижан, 170100</p></bio><bio xml:lang="en"><p>Marifat Ganieva, Cand. of Sci. (Medicine), Associate Professor, Department of Hospital Pediatrics</p><p>1, S.Yu. Otabekova str., Andijan, 170100</p></bio><email xlink:type="simple">ganieva.marifat@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-1014-5428</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Холматов</surname><given-names>Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kholmatov</surname><given-names>D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Холматов Даврон, канд. мед. наук, доцент кафедры госпитальной педиатрии</p><p>ул. С.Ю. Отабекова, д. 1, г. Андижан, 170100</p></bio><bio xml:lang="en"><p>Davron Kholmatov, Cand. of Sci. (Medicine), Associate Professor, Department of Hospital Pediatrics</p><p>1, S.Yu. Otabekova str., Andijan, 170100</p></bio><email xlink:type="simple">xolmatovd456@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-6817-0935</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ефименко</surname><given-names>О.</given-names></name><name name-style="western" xml:lang="en"><surname>Efimenko</surname><given-names>O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ефименко Оксана, канд. мед. наук, доцент кафедры госпитальной педиатрии</p><p>ул. С.Ю. Отабекова, д. 1, г. Андижан, 170100</p></bio><bio xml:lang="en"><p>Oksana Efimenko, Cand. of Sci. (Medicine), Associate Professor, Department of Hospital Pediatrics</p><p>1, S.Yu. Otabekova str., Andijan, 170100</p></bio><email xlink:type="simple">yefimenkooksana1955@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7361-9953</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рахманова</surname><given-names>Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Rakhmanova</surname><given-names>L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рахманова Лола, д-р мед. наук, доцент кафедры внутренних болезней в семейной медицине № 2</p><p>ул. С.А. Фаробий, д. 2, г. Ташкент, 100109</p></bio><bio xml:lang="en"><p>Lola Rakhmanova, Dr. of Sci. (Medicine), Associate Professor, Department of Internal Diseases in family medicine No 2</p><p>2, S.A. Farobiy str., Tashkent, 100109</p></bio><email xlink:type="simple">lola.rahmanova61@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Андижанский государственный медицинский институт</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Аndijan State Мedical Institute</institution><country>Uzbekistan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Ташкентский государственный медицинский университет</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Tаshkent State Medical University</institution><country>Uzbekistan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2025</year></pub-date><volume>16</volume><issue>4</issue><fpage>49</fpage><lpage>57</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Boltaboeva М., Haydarov A., Ganieva M., Kholmatov D., Efimenko O., Rakhmanova L., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Болтабоева М., Хайдаров А., Ганиева М., Холматов Д., Ефименко О., Рахманова Л.</copyright-holder><copyright-holder xml:lang="en">Boltaboeva М., Haydarov A., Ganieva M., Kholmatov D., Efimenko O., Rakhmanova L.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sechenovmedj.com/jour/article/view/1344">https://www.sechenovmedj.com/jour/article/view/1344</self-uri><abstract><p>Alport syndrome (AS) is a hereditary nephropathy caused by mutations in the COL4A3, COL4A4, and COL4A5 genes. Rare contiguous COL4A5–COL4A6 alterations cause AS with diffuse leiomyomatosis (AS-DL).</p><sec><title>Case report</title><p>Case report. A 16-year-old male had mild proteinuria, hematuria, hearing loss and myopia since childhood. Estimated glomerular filtration rate was 82.8 mL/min/1.73 m². Kidney biopsy showed segmental mesangial sclerosis; immunofluorescence was negative. Electron microscopy demonstrated diffuse glomerular basement membrane thinning and podocyte foot-process effacement. Two deceased brothers had end stage kidney disease; the mother had hematuria, uterine myoma, and a benign bladder tumor. A diagnosis of X-linked AS was established according to the Flinter criteria and nephroprotective treatment was initiated. Since 2024, the patient had complained of epigastric symptoms. An endoscopy revealed a 2-cm gastric submucosal lesion. A whole-exome sequencing identified a hemizygous missense variant in COL4A5 and a COL4A6 exon 1–2 deletion, confirming AS-DL.</p></sec><sec><title>Discussion</title><p>Discussion. This case demonstrates the co-occurrence of AS-DL and shows that early pedigree assessment, combined with integrated clinicopathologic-genetic evaluation in a multidisciplinary framework, enables a timely diagnosis of atypical familial AS-DL and improves clinical management.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Синдром Альпорта (СА) – наследственная нефропатия, обусловленная мутациями в генах COL4A3, COL4A4 и COL4A5. Редкие смежные варианты COL4A5–COL4A6 вызывают СА с диффузным лейомиоматозом (СА-ДЛ).</p><sec><title>Описание случая</title><p>Описание случая. У 16-летнего пациента с детства отмечались умеренная протеинурия, гематурия, снижение слуха и миопия. Расчетная СКФ – 82,8 мл/мин/1,73 м2. Биопсия почки: сегментарный мезангиальный склероз; иммунная флюоресценция отрицательна. Электронная микроскопия: диффузное истончение гломерулярной базальной мембраны и слияние ножек подоцитов. Двое братьев с терминальной почечной недостаточностью умерли в подростковом возрасте; у матери – гематурия, миома матки и доброкачественная опухоль мочевого пузыря. Диагноз Х-сцепленного СА установлен по критериям Флинтера; начата нефропротективная терапия. С 2024 года появились эпигастральные жалобы; эндоскопия выявила подслизистое образование желудка размером 2 см. Полногеномное секвенирование обнаружило гемизиготный миссенс-вариант в COL4A5 и делецию экзонов 1–2 COL4A6, что подтвердило СА-ДЛ.</p></sec><sec><title>Обсуждение</title><p>Обсуждение. Представленный случай демонстрирует сочетание СА с ДЛ и показывает, что ранний семейный скрининг в сочетании с мультидисциплинарным клиническим, гистопатологическим и генетическим обследованием обеспечивает своевременную диагностику атипичных семейных форм СА-ДЛ и улучшает тактику ведения пациентов.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>лейомиома</kwd><kwd>нефритический синдром</kwd><kwd>опухоли матки</kwd><kwd>Х-сцепленные генетические заболевания</kwd><kwd>опухоли гладкой мускулатуры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>leiomyoma</kwd><kwd>nephritic syndrome</kwd><kwd>uterine neoplasms</kwd><kwd>X-linked genetic diseases</kwd><kwd>smooth muscle tumors</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки (собственные ресурсы).</funding-statement><funding-statement xml:lang="en">The study had no sponsorship (own resources).</funding-statement></funding-group></article-meta></front><body><sec><title>Abbreviations:</title><p>Аlpоrt syndrоme (АS) is а hereditary disease defined by progressive kidney fаilure, sensоrineurаl heаring lоss, аnd ocular abnormalities. AS results from pathogenic variants in СОL4А3, СОL4А4, оr СОL4А5 genes, which enсоde type IV соllаgen, a structural component essential to the integrity of the glomerular basement membrane [1–4]. The most frequent form is X-linked AS caused by COL4A5 variants; COL4A3 and COL4A4 variants typically underlie autosomal-recessive disease. The prevalence of AS is estimated at approximately 1 per 5000–10,000 individuals; but the true burden is probably higher because of late recognition and atypical presentations, particularly among females with lyonization-mediated variability [<xref ref-type="bibr" rid="cit5">5</xref>][<xref ref-type="bibr" rid="cit6">6</xref>].</p><p>A subset of individuals with X-linked AS develop diffuse leiomyomatosis (DL) due to contiguous deletions involving COL4A5 and COL4A6, with reported rates of roughly 2–5% [<xref ref-type="bibr" rid="cit7">7</xref>]. By 2021, only around 30 families with genetically confirmed AS-DL had been described worldwide [<xref ref-type="bibr" rid="cit8">8</xref>]. DL is more frequently observed in women and most often involves the esophagus, trасheа, and genital tract, requiring multidisciplinary care [<xref ref-type="bibr" rid="cit9">9</xref>][<xref ref-type="bibr" rid="cit10">10</xref>].</p><p>Heterоzygоus СОL4А3 оr СОL4А4 vаriаnts mаy manifest with isolated prоteinuriа and fосаl segmentаl glоmerulоsсlerоsis, withоut the classic осulаr аnd аuditоry symptoms, whiсh саn оften leаd tо misdiаgnоsis [11–14]. Recent studies also implicate digenic inheritance, mosaic variants, and deep intronic changes as contributors to disease pathogenesis and to the breadth of phenotypes observed. These findings support the incorporation of expanded genetic testing into routine evaluation, especially when the clinical picture is atypical [<xref ref-type="bibr" rid="cit9">9</xref>][<xref ref-type="bibr" rid="cit15">15</xref>][<xref ref-type="bibr" rid="cit16">16</xref>]. In a recent paper, a child with X-linked AS was diagnosed with esophageal DL, emphasizing the usefulness of integrating clinical evaluation, histology, and family studies for early detection of non-renal manifestations [<xref ref-type="bibr" rid="cit17">17</xref>].</p><p>Thе аim of this case report is tо describe a rаre fаmiliаl co-occurrence of AS аnd DL, аnd tо emphasize the diаgnostic value оf cоmbining gеnealоgical assessment with сliniсal examination, renal histоlogy, аnd gеnetic testing.</p></sec><sec><title>CASE REPORT</title><p>A 16-year-old patient had been followed for eleven years at the Nephrоlоgy Depаrtment оf the Andijan Regional Multidisciplinary Children’s Medical Center for suspected AS. He reported long-standing microscopic hematuria, mild proteinuria, progressive decline in hearing, and myopia. Maternal pregnancy was complicated by first-trimester toxicosis; the patient was delivered at term with a birth weight of 4200 g and was breastfed until three years of age. Past medical history included pneumonia, recurrent tonsillitis, and repeated upper-respiratory infections (6–8 episodes per year).</p><p>The pedigree suggested X-linked transmission (Fig. 1). Two elder brothers died in adolescence from end-stage kidney disease attributed to glomerulonephritis. The patient’s mother had adolescent-onset hematuria, underwent surgery for symptomatic uterine myoma at age 36 after unsuccessful medical therapy, and three years before the proband’s evaluation was found to have a benign bladder tumor (histologic subtype not available). Chemotherapy was recommended at that time and was followed by increased hematuria. She had not undergone genetic testing for AS, and no additional genealogic information from maternal grandparents or siblings was available.</p><fig id="fig-1"><caption><p>FIG. 1. Pedigree chart of family Alport syndrome with diffuse leiomyomatosis</p></caption><graphic xlink:href="sechenov-16-4-g001.jpeg"><uri content-type="original_file">https://cdn.elpub.ru/assets/journals/sechenov/2025/4/13wh7UCH29wqhwJuj12sJyyNgzIEo55bgF3mczj0.jpeg</uri></graphic></fig><p>In 2019 proband underwent a kidney biopsy. Three renal cores (total length 37 mm) were obtained, with a 1.5-mm cortical fragment reserved for electron microscopy. Light microscopy demonstrated a mesangial and sclerosing pattern with segmental mesangial sclerosis (Fig. 2A). Interstitial fibrosis involved approximately 10% of the cortical area. Immunofluorescence showed no specific glomerular deposition (Fig. 2B). Congo red staining for amyloid was not performed. Electron microscopy revealed diffuse thinning of glomerular basement membrane with podocyte foot-process effacement, consistent with AS (Fig. 2C).</p><fig id="fig-2"><caption><p>FIG. 2. Kidney biopsy of proband with Alport syndrome and diffuse leiomyomatosis</p><p>A. Light microscopy (hematoxylin and eosin, magnification ×400). A total of 30 glomeruli were identified, of which 4 were globally sclerosed. Some glomeruli showed segmental sclerosis with adhesions to Bowman’s capsule. Mesangial hypercellularity: mild. Mesangial matrix expansion: mild. Glomerular hypertrophy: moderate. Tubular epithelial cells contained reabsorption droplets. Tubular atrophy involved approximately 10% of the cortical area. Interstitial inflammation involved about 3% of the cortex. The interstitium showed fibrosis and mononuclear cellular infiltrates with numerous foam cells. Arteries and arterioles appeared unremarkable.B. Immunofluorescence study (paraffin-embedded kidney blocks, magnification ×200). No specific fluorescence for IgA, IgG, IgM, C3, or C1q.C. Electron microscopy (one glomerulus, magnification ×10,000). Diffuse effacement of podocyte foot processes. Glomerular basement membranes exhibited areas of thinning and thickening with marked lamellation and splitting.</p></caption><graphic xlink:href="sechenov-16-4-g002.jpeg"><uri content-type="original_file">https://cdn.elpub.ru/assets/journals/sechenov/2025/4/csVHXMpMXxZuFI65MkfnUSjNWH7CyepMvKwna9EN.jpeg</uri></graphic></fig><p>Electrocardiography revealed sinus rhythm with a normal electrical axis. Renal ultrasonography demonstrated diffuse parenchymal changes without hydronephrosis. An ophthalmologic assessment showed grade II myopia; anterior lenticonus and dot-and-fleck retinopathy were not documented. Audiometry demonstrated bilateral grade III mixed hearing loss (Fig. 3).</p><fig id="fig-3"><caption><p>FIG. 3. Audiogram of proband with Alport syndrome and diffuse leiomyomatosis</p><p>Note: air conduction (red), bone conduction (blue).</p></caption><graphic xlink:href="sechenov-16-4-g003.jpeg"><uri content-type="original_file">https://cdn.elpub.ru/assets/journals/sechenov/2025/4/fJXl97G73EL5EXwKV5GrHCSqRbT2jDWEasBaBePd.jpeg</uri></graphic></fig><p>Integrating the clinical phenotype (hematuria, proteinuria, mixed hearing loss, myopia), the histopathologic features, and the family history of adolescent renal failure in male relatives, a diagnosis of X-linked AS was established according to Flinter criteria [<xref ref-type="bibr" rid="cit18">18</xref>]. At that time, molecular testing was not available. Nephroprotective treatment with angiotensin converting enzyme inhibitors was initiated.</p><p>Since 2024, the patient complained of fatigue, epigastric pain, nausea, and vomiting. A cardiopulmonary examination did not show up anything.</p><p>Laboratory testing indicated moderate anemia – hemoglobin 89 g/L, red blood cells 3.6×10¹²/L (RBC) and mild leukopenia (leukocytes 3.9×10⁹/L). Serum biochemistry showed total protein 54 g/L, creatinine 116 μmol/L, urea 9.2 mmol/L, with an estimated glomerular filtration rate of 82.8 mL/min/1.73 m². Urinalysis revealed protein 0.33 g/L, white blood cells 6–8 per high-power field, dysmorphic RBCs 10–12, isomorphic RBCs 4–6, and hyaline casts 2–5.</p><p>In July 2025, an upper endoscopy was performed and identified a 2-cm submucosal lesion in the body of the stomach (Fig. 4). The endoscopic appearance was consistent with a smooth-muscle neoplasm, and surgical resection was recommended. The patient remained clinically stable under a joint follow-up by gastroenterology and pediatric surgery while preoperative work-up was arranged.</p><fig id="fig-4"><caption><p>FIG. 4. Upper endoscopy of proband with Alport syndrome and diffuse leiomyomatosis</p><p>Note: submucosal gastric lesion located in the body of the stomach measuring 2 cm (arrow).</p></caption><graphic xlink:href="sechenov-16-4-g004.jpeg"><uri content-type="original_file">https://cdn.elpub.ru/assets/journals/sechenov/2025/4/ccz2BTrhxVH6Q4CtjMKx4S7wUBCBaxjPXBYKgtUI.jpeg</uri></graphic></fig><p>In light of the clinical features suggestive of AS and the additional identification of a gastric smooth muscle neoplasm consistent with DL, molecular genetic testing was warranted to confirm the diagnosis and guide appropriate clinical management. Whole-exome sequencing identified two pathogenic alterations: a hemizygous missense variant in COL4A5 (NM_000495.5:c.2879G&gt;A, p.Gly960Asp), consistent with X-linked AS and affecting the α5(IV) collagen chain, and a deletion encompassing exons 1–2 of COL4A6 (NM_000096.4), indicative of a contiguous COL4A5–COL4A6 rearrangement on the X chromosome that underlies DL associated with AS. Both variants were classified as pathogenic based on current annotations in the OMIM (Online Mendelian Inheritance in Man) database1 and interpreted according to the American College of Medical Genetics and Genomics guidelines2. The classification may be subject to revision as additional evidence accumulates.</p></sec><sec><title>DISCUSSION</title><p>АS is а prоgrеssivе cоngеnitаl nеphrоpаthy caused by type IV collagen defects and classically involves kidneys, hearing, and eyes. Thе X-linkеd dоminаnt fоrm is mоrе cоmmоn [<xref ref-type="bibr" rid="cit8">8</xref>]. Our patient showed the renal-auditory phenotype early on and, at 16 years, developed epigastric symptoms. An endoscopy revealed a 2-cm submucosal lesion in the gastric body, compatible with smooth-muscle proliferations seen in AS with DL.</p><p>Family history strengthens the inference of X-linked inheritance: two elder brothers died in adolescence from end-stage kidney disease, and the patient’s mother had adolescent-onset hematuria, underwent surgery for uterine myoma at 36 years, and later a benign bladder tumor. Thеsе clinicаl fеаturеs mаy suggеst а rаrе fоrm оf АS роtеntiаlly cаusеd by micrоdеlеtiоns in thе COL4A5 and COL4A6 genes [<xref ref-type="bibr" rid="cit7">7</xref>][<xref ref-type="bibr" rid="cit19">19</xref>]. However, а dirеct аssоciаtiоn bеtwееn utеrinе fibrоids аnd АS hаs nоt bееn clеаrly dеmоnstrаtеd аt еithеr thе clinicаl оr gеnеtic lеvеl. Moreover, uterine fibroids are common, and a direct causal relationship with AS cannot be assumed without genetic confirmation. This саse mаy аlsо be а pоssible exаmple оf AS being milder disease expression in females compared to males.</p><p>Thе mоthеr’s nоnsреcific symрtоms аnd thе оccurrеncе оf еnd-stаgе kidney fаilurе in twо brоthеrs rеflесt sеvеrе оutcоmеs оf dеlаyеd gеnеtic аssеssmеnt. Thе реdigrее suppоrts X-linkеd inhеritаncе аnd illustrаtеs vаriаblе multi-оrgаn invоlvеmеnt. Соnсurrent invоlvеmеnt оf kidnеys, еаrs, еyеs, stоmасh, аnd utеrus is syndrоmic аnd undеrscоrеs nееd fоr multidisсiplinаry соnsultаtiоn. Thеsе оbservаtiоns rеinfоrсе thе vаluе оf multidisсiplinаry mаnаgеmеnt in AS-DL, with rеgulаr fоllоw-up by nеphrоlоgists, аudiоlоgists, оphthаlmоlоgists, аnd gаstrоеntеrоlоgists tо fасilitаtе еаrly dеtесtiоn аnd timеly intеrvеntiоn.</p><p>Clinicopathologic correlation was consistent. A kidney biopsy showed segmental mesangial sclerosis with 10% interstitial fibrosis and classic ultrastructural abnormalities of the glomerular basement membrane. Immunofluorescence revealed no immunoglobulin or complement deposition, supporting a structural basement-membrane disorder rather than immune-complex disease. An audiometry confirmed bilateral grade III mixed hearing loss, and ophthalmologic assessment documented myopia, aligning with the recognised extra-renal spectrum of AS. Recurrent upper-respiratory infections mаy indicаtе undеrlying immunоlоgicаl dysfunctiоn, роssibly аssоciаtеd with АS [<xref ref-type="bibr" rid="cit15">15</xref>][<xref ref-type="bibr" rid="cit20">20</xref>].</p><p>In this patient, kidney function was relatively preserved (estimated glomerular filtration rate 82.8 mL/min/1.73 m²). This finding may suggest a slowly progressive clinical phenotype of the AS rather than a rapid decline often seen in adolescent males with X-linked disease. Nonetheless, AS is typically progressive, and vigilant surveillance is warranted. Priorities include renin-angiotensin-aldosterone system blockade as tolerated, periodic assessment of proteinuria and glomerular filtration rate, and longitudinal audiologic and ophthalmologic follow-up [<xref ref-type="bibr" rid="cit21">21</xref>].</p><p>This case also illustrates diagnostic pathways when access to molecular testing is limited. A structured approach that integrates pedigree analysis, multi-organ evaluation, and kidney pathology can establish a presumptive diagnosis and triage patients for genetic confirmation when feasible [22–24]. The genetic counselling for at-risk relatives cаn sеrvе аs а рrаcticаl аnd cоst-еffеctivе аltеrnаtivе tо mоlеculаr аnаlysis and diagnosis could be established according to Flinter criteria [<xref ref-type="bibr" rid="cit18">18</xref>].</p></sec><sec><title>CONCLUSION</title><p>This case demоnstrаtes X-linked AS with DL, highlighting multisystem expression and familial burden. The deaths of two brothers with сhrоniс kidney fаilure and the mother’s long-standing hematuria with leiomyomatous disease emphаsizes the impоrtаnсe оf timely geneаlоgiсаl аnаlysis аnd а multidisсiplinаry аpprоасh for early diagnosis. Genealogic assessment аnd tаrgeted genetiс testing enаble сliniсiаns tо асhieve better оutсоmes fоr pаtients аnd their relаtives in the cases оf аtypiсаl hereditаry diseаses.</p></sec><sec><title>AUTHORS CONTRIBUTIONS</title><p>Muqaddas Boltaboeva contributed to the conceptualization, and preparation of the original draft. Muqaddas Boltaboeva and Marifat Ganieva participated in compiling the data curation and the research. Marifat Ganieva, Oksana Efimenko and Davron Kholmatov contributed to the review and editing of the text. Abdulhamid Haydarov performed the formal analysis. Lola Rakhmanova contributed to the methodology and provided supervision throughout the study. All authors approved the final version of the article.</p><p>Compliance with ethical standards. Consent statement. The patient’s parents consented to the publication of the article “Familial co-occurrence of diffuse leiomyomatosis and Alport syndrome: a clinical case report” in the “Sechenov Medical Journal”. Ethical approval for conducting the study was granted by the Ethics Committee of Andijan State Medical Institute (Approval No: 4/80, dated: 12.05.2025).</p><p>Conflict of interests. The authors declare that there is no conflict of interest.</p><p>Financing. The study had no sponsorship (own resources).</p><p>1. An Online Catalog of Human Genes and Genetic Disorders. https://www.omim.org/ (access date: 12.06.2025).2. American College of Medical Genetics and Genomics guidelines. 2018. https://www.acmg.net (access date: 12.06.2025).</p></sec></body><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gregorio V., Caparali E.B., Shojaei A., et al. Alport syndrome: Clinical spectrum and therapeutic advances. Kidney Med. 2023 Mar; 5(5): 100631. https://doi.org/10.1016/j.xkme.2023.100631. PMID: 37122389</mixed-citation><mixed-citation xml:lang="en">Gregorio V., Caparali E.B., Shojaei A., et al. Alport syndrome: Clinical spectrum and therapeutic advances. Kidney Med. 2023 Mar; 5(5): 100631. https://doi.org/10.1016/j.xkme.2023.100631. PMID: 37122389</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Huang H.X., Tsai I.J., Greenbaum L.A. Alport syndrome: Expanding diagnosis and treatment. Pediatr Neonatol. 2025 Feb; 66(Suppl1): S13–S17. https://doi.org/10.1016/j.pedneo.2024.10.005. Epub 2024 Oct 30. PMID: 39521677</mixed-citation><mixed-citation xml:lang="en">Huang H.X., Tsai I.J., Greenbaum L.A. Alport syndrome: Expanding diagnosis and treatment. Pediatr Neonatol. 2025 Feb; 66(Suppl1): S13–S17. https://doi.org/10.1016/j.pedneo.2024.10.005. Epub 2024 Oct 30. PMID: 39521677</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Puapatanakul P., Miner J.H. Alport syndrome and Alport kidney diseases – elucidating the disease spectrum. Curr Opin Nephrol Hypertens. 2024 May; 33(3): 283–290. https://doi.org/10.1097/MNH.0000000000000983. Epub 2024 Mar 13. PMID: 38477333</mixed-citation><mixed-citation xml:lang="en">Puapatanakul P., Miner J.H. Alport syndrome and Alport kidney diseases – elucidating the disease spectrum. Curr Opin Nephrol Hypertens. 2024 May; 33(3): 283–290. https://doi.org/10.1097/MNH.0000000000000983. Epub 2024 Mar 13. PMID: 38477333</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Savige J. Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities. Kidney Int Rep. 2022 Jun; 7(9): 1933–1938. https://doi.org/10.1016/j.ekir.2022.06.001. PMID: 36090501</mixed-citation><mixed-citation xml:lang="en">Savige J. Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities. Kidney Int Rep. 2022 Jun; 7(9): 1933–1938. https://doi.org/10.1016/j.ekir.2022.06.001. PMID: 36090501</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gibson J., Fieldhouse R., Chan M.M.Y., et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol. 2021 Sep; 32(9): 2273–2290. https://doi.org/10.1681/ASN.2020071065. Epub 2021 Jun 18. PMID: 34400539</mixed-citation><mixed-citation xml:lang="en">Gibson J., Fieldhouse R., Chan M.M.Y., et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol. 2021 Sep; 32(9): 2273–2290. https://doi.org/10.1681/ASN.2020071065. Epub 2021 Jun 18. PMID: 34400539</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Torra R., Lipska-Zietkiewicz B., Acke F., et al. Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025 May; 40(6): 1091-1106. https://doi.org/10.1093/ndt/gfae265. PMID: 39673454</mixed-citation><mixed-citation xml:lang="en">Torra R., Lipska-Zietkiewicz B., Acke F., et al. Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025 May; 40(6): 1091-1106. https://doi.org/10.1093/ndt/gfae265. PMID: 39673454</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou X., Wang J., Mao J., Ye Q. Clinical manifestations of Alport syndrome-diffuse leiomyomatosis patients with contiguous gene deletions in COL4A6 and COL4A5. Front Med (Lausanne). 2021 Oct; 8: 766224. https://doi.org/10.3389/fmed.2021.766224. PMID: 34778325</mixed-citation><mixed-citation xml:lang="en">Zhou X., Wang J., Mao J., Ye Q. Clinical manifestations of Alport syndrome-diffuse leiomyomatosis patients with contiguous gene deletions in COL4A6 and COL4A5. Front Med (Lausanne). 2021 Oct; 8: 766224. https://doi.org/10.3389/fmed.2021.766224. PMID: 34778325</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Takeda F.R., De Meira J.D. Junior, Sallum R.A.A. A case report of esophageal leiomyoma in Alport’s syndrome treated with roboticassisted distal myotomy: A surgical technique to avoid esophagectomy. International Journal of Surgery Case Reports. 2023 Jun; 108: 108433. https://doi.org/10.1016/j.ijscr.2023.108433. PMID: 37352772</mixed-citation><mixed-citation xml:lang="en">Takeda F.R., De Meira J.D. Junior, Sallum R.A.A. A case report of esophageal leiomyoma in Alport’s syndrome treated with roboticassisted distal myotomy: A surgical technique to avoid esophagectomy. International Journal of Surgery Case Reports. 2023 Jun; 108: 108433. https://doi.org/10.1016/j.ijscr.2023.108433. PMID: 37352772</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kashtan C.E. Alport syndrome: Achieving early diagnosis and treatment. Am J Kidney Dis. 2021 Feb; 77(2): 272–279. https://doi.org/10.1053/j.ajkd.2020.03.026. Epub 2020 Jul 22. PMID: 32712016</mixed-citation><mixed-citation xml:lang="en">Kashtan C.E. Alport syndrome: Achieving early diagnosis and treatment. Am J Kidney Dis. 2021 Feb; 77(2): 272–279. https://doi.org/10.1053/j.ajkd.2020.03.026. Epub 2020 Jul 22. PMID: 32712016</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева Т.А., Аксенова М.Е., Заикова Н.М. Особенности течения и диагностики Х-сцепленного синдрома Альпорта с диффузным лейомиоматозом желудочно-кишечного тракта: клинический случай. Нефрология и диализ. 2025; 27(2): 228–229. https://doi.org/10.28996/2618-9801-2025-2-228-229. EDN: ABCXTZ</mixed-citation><mixed-citation xml:lang="en">Alekseeva T.A., Aksenova M.E., Zaikova N.M. Characteristics of the course and diagnostics of X-linked Alport syndrome with diffuse leiomyomatosis of the gastrointestinal tract: a clinical case. Nephrology and Dialysis. 2025; 27(2): 228– 229 (In Russ.). https://doi.org/10.28996/2618-9801-2025-2-228- 229. EDN: ABCXTZ</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gatseva A., Sin Y.Y., Brezzo G., Van Agtmael T. Basement membrane collagens and disease mechanisms. Essays Biochem. 2019 Sep; 63(3): 297–312. https://doi.org/10.1042/EBC20180071. PMID: 31387942</mixed-citation><mixed-citation xml:lang="en">Gatseva A., Sin Y.Y., Brezzo G., Van Agtmael T. Basement membrane collagens and disease mechanisms. Essays Biochem. 2019 Sep; 63(3): 297–312. https://doi.org/10.1042/EBC20180071. PMID: 31387942</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J.M., Nozu K., Choi D.E., et al. Features of autosomal recessive Alport syndrome: A systematic review. J Clin Med. 2019 Feb; 8(2): 178. https://doi.org/10.3390/jcm8020178. PMID: 30717457</mixed-citation><mixed-citation xml:lang="en">Lee J.M., Nozu K., Choi D.E., et al. Features of autosomal recessive Alport syndrome: A systematic review. J Clin Med. 2019 Feb; 8(2): 178. https://doi.org/10.3390/jcm8020178. PMID: 30717457</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Böckhaus J., Wang F., et al. Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol. 2021 Sep; 36(9): 2719–2730. https://doi.org/10.1007/s00467-021-05040-9. Epub 2021 Mar 27. PMID: 33772369</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Böckhaus J., Wang F., et al. Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol. 2021 Sep; 36(9): 2719–2730. https://doi.org/10.1007/s00467-021-05040-9. Epub 2021 Mar 27. PMID: 33772369</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Shulman C., Liang E., Kamura M., et al. Type IV collagen variants in CKD: Performance of computational predictions for identifying pathogenic variants. Kidney Med. 2021 Feb; 3(2): 257–266. https://doi.org/10.1016/j.xkme.2020.12.007. PMID: 33851121</mixed-citation><mixed-citation xml:lang="en">Shulman C., Liang E., Kamura M., et al. Type IV collagen variants in CKD: Performance of computational predictions for identifying pathogenic variants. Kidney Med. 2021 Feb; 3(2): 257–266. https://doi.org/10.1016/j.xkme.2020.12.007. PMID: 33851121</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Savige J., Lipska-Zietkiewicz B.S., Watson E., et al. Guidelines for genetic testing and management of Alport syndrome. Clin J Am Soc Nephrol. 2022 Jan; 17(1): 143–154. https://doi.org/10.2215/CJN.04230321. Epub 2021 Dec 20. Erratum in: Clin J Am Soc Nephrol. 2023 Apr 1; 18(4): 510. https://doi.org/10.2215/CJN.0000000000000095. PMID: 34930753</mixed-citation><mixed-citation xml:lang="en">Savige J., Lipska-Zietkiewicz B.S., Watson E., et al. Guidelines for genetic testing and management of Alport syndrome. Clin J Am Soc Nephrol. 2022 Jan; 17(1): 143–154. https://doi.org/10.2215/CJN.04230321. Epub 2021 Dec 20. Erratum in: Clin J Am Soc Nephrol. 2023 Apr 1; 18(4): 510. https://doi.org/10.2215/CJN.0000000000000095. PMID: 34930753</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Groopman E.E., Marasa M., Cameron-Christie S., et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019 Jan; 380(2): 142–151. https://doi.org/10.1056/NEJMoa1806891. Epub 2018 Dec 26. PMID: 30586318</mixed-citation><mixed-citation xml:lang="en">Groopman E.E., Marasa M., Cameron-Christie S., et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019 Jan; 380(2): 142–151. https://doi.org/10.1056/NEJMoa1806891. Epub 2018 Dec 26. PMID: 30586318</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Thanachatchairattana P., Losty P. Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome. BMJ Case Rep. 2024 Aug; 17(8): e260442. https://doi.org/10.1136/bcr-2024-260442. PMID: 39179268</mixed-citation><mixed-citation xml:lang="en">Thanachatchairattana P., Losty P. Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome. BMJ Case Rep. 2024 Aug; 17(8): e260442. https://doi.org/10.1136/bcr-2024-260442. PMID: 39179268</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Flinter F.A., Cameron J.S., Chantler C., et al. Genetics of classic Alport’s syndrome. Lancet. 1988 Oct; 2(8618): 1005–1007. https://doi.org/10.1016/s0140-6736(88)90753-2. PMID: 2902439</mixed-citation><mixed-citation xml:lang="en">Flinter F.A., Cameron J.S., Chantler C., et al. Genetics of classic Alport’s syndrome. Lancet. 1988 Oct; 2(8618): 1005–1007. https://doi.org/10.1016/s0140-6736(88)90753-2. PMID: 2902439</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chen F., Ahimaz P., Nguyen Q.M., et al. Phenotype driven molecular genetic test recommendation for diagnosing pediatric rare disorders. NPJ Digit Med. 2024 Nov; 7(1): 333. https://doi.org/10.1038/s41746-024-01331-1. PMID: 39572625</mixed-citation><mixed-citation xml:lang="en">Chen F., Ahimaz P., Nguyen Q.M., et al. Phenotype driven molecular genetic test recommendation for diagnosing pediatric rare disorders. NPJ Digit Med. 2024 Nov; 7(1): 333. https://doi.org/10.1038/s41746-024-01331-1. PMID: 39572625</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Аксенова М.Е. Синдром Альпорта: современные представления. Нефрология. 2021; 25(3): 75–83. https://doi.org/10.36485/1561-6274-2021-25-3-75-83. EDN: LYSGFH</mixed-citation><mixed-citation xml:lang="en">Aksenova M.E. Alport syndrome: our knowledge update. Nephrology (Saint-Petersburg). 2021; 25(3): 75–83 (In Russ.). https://doi. org/10.36485/1561-6274-2021-25-3-75-83. EDN: LYSGFH</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr; 105(4S): S117–S314. https://doi.org/10.1016/j.kint.2023.10.018. PMID: 38490803</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr; 105(4S): S117–S314. https://doi.org/10.1016/j.kint.2023.10.018. PMID: 38490803</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gibson J.T., de Gooyer M., Huang M., Savige J. A systematic review of pathogenic COL4A5 variants and proteinuria in women and girls with X-linked Alport syndrome. Kidney Int Rep. 2022 Aug; 7(11): 2454–2461. https://doi.org/10.1016/j.ekir.2022.08.021. PMID: 36531881</mixed-citation><mixed-citation xml:lang="en">Gibson J.T., de Gooyer M., Huang M., Savige J. A systematic review of pathogenic COL4A5 variants and proteinuria in women and girls with X-linked Alport syndrome. Kidney Int Rep. 2022 Aug; 7(11): 2454–2461. https://doi.org/10.1016/j.ekir.2022.08.021. PMID: 36531881</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J.H., Lim S.H., Song J.Y., et al. Genotype-phenotype correlation of X-linked Alport syndrome observed in both genders: a multicenter study in South Korea. Sci Rep. 2023 Apr; 13(1): 6827. https://doi.org/10.1038/s41598-023-34053-7. PMID: 37100867</mixed-citation><mixed-citation xml:lang="en">Kim J.H., Lim S.H., Song J.Y., et al. Genotype-phenotype correlation of X-linked Alport syndrome observed in both genders: a multicenter study in South Korea. Sci Rep. 2023 Apr; 13(1): 6827. https://doi.org/10.1038/s41598-023-34053-7. PMID: 37100867</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Matthaiou A., Poulli T., Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J. 2020 Feb; 13(6): 1025–1036. https://doi.org/10.1093/ckj/sfz176. PMID: 33391746</mixed-citation><mixed-citation xml:lang="en">Matthaiou A., Poulli T., Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J. 2020 Feb; 13(6): 1025–1036. https://doi.org/10.1093/ckj/sfz176. PMID: 33391746</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
